BRL 103
Alternative Names: BRL-103Latest Information Update: 03 Aug 2022
At a glance
- Originator Shanghai Bioray Laboratory
- Developer BRL Medicine
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Beta-thalassaemia
Most Recent Events
- 19 Jul 2022 Clinical trials in Beta-thalassaemia in China (Parenteral) (BRL Medicine pipeline; July 2022)
- 12 Jul 2022 Preclinical trials in Beta-thalassaemia in China (Parenteral) (BRL Medicine pipeline; July 2022)
- 07 Jul 2022 Bioray Laboratories plans a phase I/II trial for Beta-thalassemia (In adolescents, In adults, In children) (Parenteral) in China (NCT05442346)